Treatment with DPP-4i versus sulphonylureas yield similar MACE risk in type 2 diabetics: Study

Related content

• Research output

• Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice

  Research output: Contribution to journal › Article › peer-review